BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity. DESIGN: In this review, we discuss the history, progress, and future potential of TαT in the treatment of prostate cancer, including dosimetry-individualized treatment planning, combinations with small-molecule therapies, and conjugation to molecules directed against antigens expressed by prostate cancer cells, such as prostate-specific membrane antigen (PSMA) or components of the tumor microenvironment. RESULTS: A clinical proof of concept that TαT is efficacious in treating bone-metastatic castration-resistant prostate cancer has been demonstrated by radium-223 via improved overall survival and long-term safety/tolerability in the phase III ALSYMPCA trial. Dosimetry calculation and pharmacokinetic measurements of TαT provide the potential for optimization and individualized treatment planning for a precision medicine-based cancer management paradigm. The ability to combine TαTs with other agents, including chemotherapy, androgen receptor (AR)-targeting agents, DNA repair inhibitors, and immuno-oncology agents, is under investigation. Currently, TαTs that specifically target prostate cancer cells expressing PSMA represents a promising therapeutic approach. Both PSMA-targeted actinium-225 and thorium-227 conjugates are under investigation. CONCLUSIONS: The described clinical benefit, safety and tolerability of radium-223 and the recent progress in TαT trial development suggest that TαT occupies an important new role in prostate cancer treatment. Ongoing studies with newer dosimetry methods, PSMA targeting, and novel approaches to combination therapies should expand the utility of TαT in prostate cancer treatment.

Advances in targeted Alpha therapy for prostate cancer / De Vincentis, G; Gerritsen, W; Gschwend, J E; Hacker, M; Lewington, V; O'Sullivan, J M; Oya, M; Pacilio, M; Parker, C; Shore, N; Sartor, O. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 30:11(2019), pp. 1728-1739. [10.1093/annonc/mdz270]

Advances in targeted Alpha therapy for prostate cancer

De Vincentis, G
Primo
;
2019

Abstract

BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity. DESIGN: In this review, we discuss the history, progress, and future potential of TαT in the treatment of prostate cancer, including dosimetry-individualized treatment planning, combinations with small-molecule therapies, and conjugation to molecules directed against antigens expressed by prostate cancer cells, such as prostate-specific membrane antigen (PSMA) or components of the tumor microenvironment. RESULTS: A clinical proof of concept that TαT is efficacious in treating bone-metastatic castration-resistant prostate cancer has been demonstrated by radium-223 via improved overall survival and long-term safety/tolerability in the phase III ALSYMPCA trial. Dosimetry calculation and pharmacokinetic measurements of TαT provide the potential for optimization and individualized treatment planning for a precision medicine-based cancer management paradigm. The ability to combine TαTs with other agents, including chemotherapy, androgen receptor (AR)-targeting agents, DNA repair inhibitors, and immuno-oncology agents, is under investigation. Currently, TαTs that specifically target prostate cancer cells expressing PSMA represents a promising therapeutic approach. Both PSMA-targeted actinium-225 and thorium-227 conjugates are under investigation. CONCLUSIONS: The described clinical benefit, safety and tolerability of radium-223 and the recent progress in TαT trial development suggest that TαT occupies an important new role in prostate cancer treatment. Ongoing studies with newer dosimetry methods, PSMA targeting, and novel approaches to combination therapies should expand the utility of TαT in prostate cancer treatment.
2019
targeted alpha therapy (TαT); prostate cancer; prostate-specific membrane antigen (PSMA); radium-223
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Advances in targeted Alpha therapy for prostate cancer / De Vincentis, G; Gerritsen, W; Gschwend, J E; Hacker, M; Lewington, V; O'Sullivan, J M; Oya, M; Pacilio, M; Parker, C; Shore, N; Sartor, O. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 30:11(2019), pp. 1728-1739. [10.1093/annonc/mdz270]
File allegati a questo prodotto
File Dimensione Formato  
De Vincentis_postprint_Alpha-therapy_2019.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 970.33 kB
Formato Adobe PDF
970.33 kB Adobe PDF
De Vincentis_Advances in targeted_2019.pdf

accesso aperto

Note: https://www.sciencedirect.com/science/article/pii/S0923753420325850
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 3.31 MB
Formato Adobe PDF
3.31 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1317405
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 35
social impact